We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Blood Test Used to Diagnosis Cancer

By LabMedica International staff writers
Posted on 06 Mar 2012
A simple blood test is being developed that may provide early detection of many different types of cancer.

The test uses infrared light to detect infinitesimal changes in the blood of a person who has a malignant growth somewhere in the body, even before the disease has metastasized.

A team of scientists at Ben-Gurion University of the Negev (BGU; Be’er Sheva, Israel) developed a device that illuminates cancer cells with less than 5 mL blood. Various molecules are released into the bloodstream of patients with cancerous growths that cause the blood to absorb infrared light slightly differently compared to that of healthy people.

In the latest clinical trial with 200 patients and a control group, the test identified specific cancers in 90% of the patients and found other types of cancer, as well. The researchers are focused on detection of common cancers, such as lung and ovarian cancer. Doctors believe that it is critical to increase cancer detection in early stages to prevent the need for long, difficult, and costly treatments in more advanced stages.

Joseph Kapelushnik, MD, who is head of the Department of Pediatric Hemato-Oncology at Soroka hospital (Be’er Sheva, Israel) said, "This investigation is still in the early stages of clinical trials. But the purpose is to develop an efficient, cheap and simple method to detect as many types of cancers as possible. We want to be able to detect cancer while a patient is still feeling good, before it has a chance to metastasize, meaning fewer treatments, less suffering and many more lives saved." More clinical trials will be conducted in the next 18 months.

Related Links:

Ben-Gurion University of the Negev
Soroka Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
06 Mar 2012  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
06 Mar 2012  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
06 Mar 2012  |   Clinical Chem.